Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248315 | 0.88 | DYRK1A (0.43) | SMN1; SMN2ALDH1A1SRCGAAMAPT | |
| SCHEMBL5963314 | 0.74 | HPGD (0.68) | SMN1; SMN2ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL11827884 | 0.74 | BRD4 (0.47) | SMN1; SMN2ALDH1A1SRCMETPARP1 | |
| SCHEMBL11775647 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2GAAMAPTKDM4EPOLB | |
| SCHEMBL11000015 | 0.72 | KDM4E (0.45) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL4544224 | 0.68 | SMN1; SMN2 (0.64) | SMN1; SMN2GAAKDM4ELMNATSHR | |
| SCHEMBL7713019 | 0.68 | MET (0.54) | SMN1; SMN2ALDH1A1SRCMETPARP1 | |
| SCHEMBL15850325 | 0.64 | MET (0.58) | SMN1; SMN2ALDH1A1METKDM4EHPGD | |
| SCHEMBL3655311 | 0.63 | TSHR (0.48) | SMN1; SMN2GAAKDM4ELMNAHSD17B10 | |
| SCHEMBL4791698 | 0.63 | TUBB4A (0.44) | ALDH1A1HPGDHSD17B10TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383269-B1 | Substituted Dihydropyrazolones for the treatment of cardiovascular diseases | BAYER IP GMBH (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| EP-2097404-B1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-27 | — | — | EP | disclosed |
| EP-2089380-B1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | BAYER IP GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-9168249-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9085572-B2 | 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-20150148381-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-28 | — | — | US | disclosed |
| EP-2265602-B1 | SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES | BAYER IP GMBH (DE) | 2015-04-08 | — | — | EP | disclosed |
| US-8987261-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2546253-B1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR THE TREATMENT OF CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER IP GMBH (DE) | 2015-01-14 | — | — | EP | disclosed |
| EP-2383269-A2 | Substituted Dihydropyrazolones for the treatment of cardiovascular diseases | Bayer Pharma AG (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015656-A2 | NEW ALKOXYPYRAZOLES | INSTITUT PASTEUR (FR) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015656-A2 | NEW ALKOXYPYRAZOLES | INSTITUT PASTEUR (FR) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | BAYER HEALTHCARE AG (DE) | 2010-02-11 | — | — | US | disclosed |
| EP-2151434-A1 | Alkoxypyrazoles and the process for their preparation | Institut Pasteur (FR) | 2010-02-10 | — | — | EP | disclosed |
| EP-2151434-A1 | Alkoxypyrazoles and the process for their preparation | Institut Pasteur (FR) | 2010-02-10 | — | — | EP | disclosed |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | US | disclosed |
| EP-1877396-B1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | SMN1; SMN2 3249/4885ALDH1A1 203/4885SRC 257/4885 |
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | DCK, THPO, QDPR | SMN1; SMN2 3690/4885ALDH1A1 722/4885SRC 238/4885 |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | DPP7, DPP4, QDPR | SMN1; SMN2 3596/4885ALDH1A1 798/4885SRC 439/4885 |
| US-20090269420-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | GLS, ATP6V1B1, PFKP | SMN1; SMN2 3307/4885ALDH1A1 454/4885SRC 696/4885 |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, HPGDS | SMN1; SMN2 3514/4885ALDH1A1 78/4885SRC 889/4885 |
| US-20150148381-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | SMN1; SMN2 3249/4885ALDH1A1 203/4885SRC 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.